SODIUM ARSENATE, HEPTAHYDRATE

Names

[ CAS No. ]:
10048-95-0

[ Name ]:
SODIUM ARSENATE, HEPTAHYDRATE

[Synonym ]:
MFCD00149179
disodium,hydrogen arsorate,heptahydrate
EINECS 231-902-4

Chemical & Physical Properties

[ Density]:
1,88 g/cm3

[ Melting Point ]:
180 °C (dec.)(lit.)

[ Molecular Formula ]:
AsH₁₅Na₂O₁₁

[ Molecular Weight ]:
312.01400

[ Exact Mass ]:
311.96300

[ PSA ]:
148.03000

[ Stability ]:
Stable. Incompatible with strong reducing agents, strong oxidizing agents, strong acids. Incompatible with iron, aluminium and zinc in the presence of water.

MSDS

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :: CG0900000

CHEMICAL NAME :: Arsenic acid, disodium salt, heptahydrate

CAS REGISTRY NUMBER :: 10048-95-0

LAST UPDATED :: 199712

DATA ITEMS CITED :: 49

MOLECULAR FORMULA :: As-H-O4.2Na.7H2-O

MOLECULAR WEIGHT :: 427.00

WISWESSER LINE NOTATION :: .NA2.AS-O2-Q2.Q7

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intramuscular

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 87360 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - guinea pig

DOSE/DURATION :: 50 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Behavioral - convulsions or effect on seizure threshold Behavioral - ataxia

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 43 mg/kg/4W-C

TOXIC EFFECTS :: Liver - other changes Endocrine - hypoglycemia Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 30 mg/kg

SEX/DURATION :: female 9 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 20 mg/kg

SEX/DURATION :: female 9 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - Central Nervous System

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 20 mg/kg

SEX/DURATION :: female 10 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - urogenital system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 120 mg/kg

SEX/DURATION :: female 10 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 120 mg/kg

SEX/DURATION :: female 10 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 40 mg/kg

SEX/DURATION :: female 9 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - other developmental abnormalities

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 40 mg/kg

SEX/DURATION :: female 9 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 40 mg/kg

SEX/DURATION :: female 9 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - body wall

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 45 mg/kg

SEX/DURATION :: female 9 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 20 mg/kg

SEX/DURATION :: female 8 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

DOSE :: 15 mg/kg

SEX/DURATION :: female 8 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - urogenital system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

DOSE :: 15 mg/kg

SEX/DURATION :: female 8 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - eye/ear

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

DOSE :: 20 mg/kg

SEX/DURATION :: female 8 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - Central Nervous System

TYPE OF TEST :: Cytogenetic analysis

MUTATION DATA

TYPE OF TEST :: Sister chromatid exchange

TEST SYSTEM :: Rodent - hamster Fibroblast

REFERENCE :: MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 104,141,1982 *** REVIEWS *** ACGIH TLV-TWA 0.01 mg(As)/m3 DTLVS* The Threshold Limit Values (TLVs) and Biological Exposure Indices (BEIs) booklet issues by American Conference of Governmental Industrial Hygienists (ACGIH), Cincinnati, OH, 1996 Volume(issue)/page/year: TLV/BEI,1997 ACGIH TLV-Confirmed human carcinogen DTLVS* The Threshold Limit Values (TLVs) and Biological Exposure Indices (BEIs) booklet issues by American Conference of Governmental Industrial Hygienists (ACGIH), Cincinnati, OH, 1996 Volume(issue)/page/year: TLV/BEI,1997 *** U.S. STANDARDS AND REGULATIONS *** MSHA STANDARD-air:TWA 0.5 mg(As)/m3 DTLVS* The Threshold Limit Values (TLVs) and Biological Exposure Indices (BEIs) booklet issues by American Conference of Governmental Industrial Hygienists (ACGIH), Cincinnati, OH, 1996 Volume(issue)/page/year: 3,16,1971 OSHA-cancer hazard CFRGBR Code of Federal Regulations. (U.S. Government Printing Office, Supt. of Documents, Washington, DC 20402) Volume(issue)/page/year: 29,1910.1018,1987 *** OCCUPATIONAL EXPOSURE LIMITS *** OEL-ARAB Republic of Egypt:TWA 0.2 mg(As)/m3 JAN 1993 OEL-AUSTRALIA:TWA 0.05 mg(As)/m3;Carcinogen JAN 1993 OEL-BELGIUM:TWA 0.2 mg(As)/m3 JAN 1993 OEL-DENMARK:TWA 0.05 mg(As)/m3 JAN 1993 OEL-FINLAND;Carcinogen JAN 1993 OEL-FRANCE:TWA 0.2 mg(As)/m3 JAN 1993 OEL-HUNGARY:STEL 0.5 mg(As)/m3;Carcinogen JAN 1993 OEL-INDIA:TWA 0.2 mg(As)/m3 JAN 1993 OEL-THE PHILIPPINES:TWA 0.5 mg(As)/m3 JAN 1993 OEL-POLAND:TWA 0.3 mg(As)/m3 JAN 1993 OEL-SWEDEN:TWA 0.03 mg(As)/m3;Carcinogen JAN 1993 OEL-SWITZERLAND:TWA 0.1 mg(As)/m3;Carcinogen JAN 1993 OEL-THAILAND:TWA 0.5 mg(As)/m3 JAN 1993 OEL-TURKEY:TWA 0.5 mg(As)/m3 JAN 1993 OEL-UNITED KINGDOM:TWA 0.2 mg(As)/m3 JAN 1993 OEL IN BULGARIA, COLOMBIA, JORDAN, KOREA check ACGIH TLV OEL IN NEW ZEALAND, SINGAPORE, VIETNAM check ACGIH TLV *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH RECOMMENDED EXPOSURE LEVEL (REL) : NIOSH REL TO ARSENIC, INORGANIC-air:CA CL 0.002 mg(As)/m3/15M REFERENCE : NIOSH* National Institute for Occupational Safety and Health, U.S. Dept. of Health, Education, and Welfare, Reports and Memoranda. Volume(issue)/page/year: DHHS #92-100,1992

Safety Information

[ Symbol ]:

GHS06, GHS08, GHS09

[ Signal Word ]:
Danger

[ Hazard Statements ]:
H301 + H331-H350-H410

[ Precautionary Statements ]:
P201-P261-P273-P301 + P310-P311-P501

[ Personal Protective Equipment ]:
Eyeshields;Faceshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges

[ Hazard Codes ]:
T,N

[ Risk Phrases ]:
45-23/25-50/53

[ Safety Phrases ]:
S53-S45-S60-S61

[ RIDADR ]:
UN 1685 6.1/PG 2

[ WGK Germany ]:
3

[ RTECS ]:
CG0900000

[ Packaging Group ]:
II

[ Hazard Class ]:
6.1

Articles

An in vitro method for estimation of arsenic relative bioavailability in soil.

J. Toxicol. Environ. Health A 76(7) , 458-78, (2013)

This report summarizes the results of a study to develop an in vitro bioaccessibility (IVBA) extraction technique for estimating the relative bioavailability (RBA) of arsenic (As) in soil. The study w...

Measurement of arsenic relative bioavailability in swine.

J. Toxicol. Environ. Health A 76(7) , 449-57, (2013)

This study describes a method for measuring the relative oral bioavailability (RBA) of arsenic (As) in soil and other soil-like media using young swine as the animal model. Groups of animals are expos...

Arsenic alters behavioral parameters and brain ectonucleotidases activities in zebrafish (Danio rerio).

Comp. Biochem. Physiol. C. Toxicol. Pharmacol. 155(4) , 566-72, (2012)

Arsenic (As) exposure has been associated with serious chronic health risk to humans including cancer and neurological disturbances. However, there are limited studies about the mechanisms behind its ...

sodium arsenate
sodium arsenate
Sodium arsenate dodecahydrate
(6R,7S)-Cefminox sodium heptahydrate
copper,sodium,dihydrogen arsorate,carbonate
disodium,hydrogen arsorate
4-((Cyclohexylamino)methyl)benzoic acid hydrochloride
1-[(2,4-Dichlorophenyl)methyl]-N-(1,1-dimethylethyl)-2-methyl-1H-indole-3-methanamine
2-Methoxy-6-(pyrazol-1-yl)-benzonitrile
1H-3-Benzazepin-7-ol, 8-chloro-2,3,4,5-tetrahydro-5-(3-iodophenyl)-3-methyl-, (S)-
2-Ethyl-6-methylpyridin-3-yl chloroformate
(4-Methyl-tetrahydro-furan-2-yl)-methanol
1-Methyl-5-phenylmethoxycarbonyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-3-carboxylic acid
Tabaisocoumarin A
N-(1-cyanocyclopentyl)-2-[4-(4-fluorobenzenesulfonyl)-1,4-diazepan-1-yl]acetamide
6-(Methoxymethyl)-2-(thiophen-2-yl)pyrimidine-4-thiol